453 related articles for article (PubMed ID: 28448171)
21. New pharmacotherapy options for multiple myeloma.
Mina R; Cerrato C; Bernardini A; Aghemo E; Palumbo A
Expert Opin Pharmacother; 2016; 17(2):181-92. PubMed ID: 26684262
[TBL] [Abstract][Full Text] [Related]
22. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
23. [New drugs in the treatment of multiple myeloma].
Oriol A; Motlló C
Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
[TBL] [Abstract][Full Text] [Related]
24. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma.
Pantani L; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Rocchi S; Martello M; Rizzello I; Terragna C; Zamagni E; Cavo M
Expert Rev Hematol; 2016 Mar; 9(3):315-23. PubMed ID: 26634945
[TBL] [Abstract][Full Text] [Related]
25. Treatment of MM: Upcoming Novel Therapies.
Lonial S
Cancer Treat Res; 2016; 169():195-205. PubMed ID: 27696264
[TBL] [Abstract][Full Text] [Related]
26. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
27. Safety of proteasome inhibitors for treatment of multiple myeloma.
Schlafer D; Shah KS; Panjic EH; Lonial S
Expert Opin Drug Saf; 2017 Feb; 16(2):167-183. PubMed ID: 27841029
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib for previously untreated multiple myeloma.
Delforge M
Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
[TBL] [Abstract][Full Text] [Related]
29. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
30. An update in treatment options for multiple myeloma in nontransplant eligible patients.
Broijl A; Sonneveld P
Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
[TBL] [Abstract][Full Text] [Related]
31. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
32. [Daratumumab--breakthrough drug in multiple myeloma therapy].
Jurczyszyn A; Kosmaczewska A; Skotnicki AB
Postepy Hig Med Dosw (Online); 2014 Nov; 68():1352-60. PubMed ID: 25531698
[TBL] [Abstract][Full Text] [Related]
33. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Salvini M; Bonello F; Boccadoro M; Larocca A
Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
[TBL] [Abstract][Full Text] [Related]
34. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
[TBL] [Abstract][Full Text] [Related]
35. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.
Bianchi G; Ghobrial IM
Leuk Lymphoma; 2013 Feb; 54(2):229-41. PubMed ID: 22897729
[TBL] [Abstract][Full Text] [Related]
37. Emerging antibodies for the treatment of multiple myeloma.
Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659
[TBL] [Abstract][Full Text] [Related]
38. Proteasome inhibitors.
Teicher BA; Tomaszewski JE
Biochem Pharmacol; 2015 Jul; 96(1):1-9. PubMed ID: 25935605
[TBL] [Abstract][Full Text] [Related]
39. Daratumumab granted breakthrough drug status.
Laubach JP; Tai YT; Richardson PG; Anderson KC
Expert Opin Investig Drugs; 2014 Apr; 23(4):445-52. PubMed ID: 24555809
[TBL] [Abstract][Full Text] [Related]
40. Novel agents in the treatment of multiple myeloma: a review about the future.
Naymagon L; Abdul-Hay M
J Hematol Oncol; 2016 Jun; 9(1):52. PubMed ID: 27363832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]